MapLight Therapeutics, Inc.
ML-007C-MA
schizophrenia
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ML-007C-MA for schizophrenia is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“ML-007C-MA Lead Asset in Development for Schizophrenia and ADP Muscarinic Receptor Agonism is the First Novel MoA Approved for Treatment of Schizophrenia in Decades”